Displacement of protein-bound aptamers with small molecules screened by fluorescence polarization

Nature Protocols

Volumn 3, Issue 4, 2008, Pages 579-587

  Hafner, Markus ^a   Vianini, Elena ^a   Albertoni, Barbara ^a   Marchetti, Laura ^a   Grüne, Imke ^a   Gloeckner, Christian ^a   Famulok, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CYTOHESIN; CYTOHESIN 1; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SCREENING; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; MOLECULAR SIZE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DOMAIN; SENSITIVITY AND SPECIFICITY;

APTAMERS, NUCLEOTIDE; DRUG EVALUATION, PRECLINICAL; FLUORESCENCE POLARIZATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; PROTEIN BINDING;

EID: 42049112740     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2008.15     Document Type: Article

References (41)

1. Cherfils, J. & Chardin, P. GEFs: Structural basis for their activation of small GTP-binding proteins. Trends Biochem. Sci. 24, 306-311 (1999).
2. Jackson, C.L. & Casanova, J.E. Turning on ARF: The Sec7 family of guanine-nucleotide-exchange factors. Trends Cell Biol, 10 (suppl. 2): 60-67 (2000).
3. Jackson, T.R., Kearns, B.G. & Theibert, A.B. Cytohesins and centaurins: mediators of PI 3-kinase-regutated ARF signaling. Trends Biochem. Sci. 25 (suppl. 10): 489-495 (2000).
4. Rossman, K.L., Der, C.J. & Sondek, J. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6 (suppl. 2): 167-180 (2005).
5. Hashimoto, S. et al. Requirement for ARF6 in breast cancer invasive activities. Proc. Natl. Acad. Sci. USA 101 (suppl. 17): 6647-6652 (2004).
6. Gonzalez-Garcia, A. et al. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7 (suppl. 3 : 219-226 (2005).
7. Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417 (suppl. 6891): 867-871 (2002).
8. Donaldson, J.G., Finazzi, D. & Klausner, R.D. Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucteotide onto ARF protein. Nature 360 (suppl. 6402): 350-352 (1992).
9. Helms, J.B. & Rothman, J.E. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature 360 (suppl. 640): 352-354 (1992).
10. Peyroche, A. et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: Involvement of specific residues of the Sec7 domain. Mol. Cell 3 (suppl. 3): 275-285 (1999).
11. Morinaga, N., Tsai, S.-C., Moss, J. & Vaughan, M. Isolation of a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP ribosylation factor (ARF) 1 and ARF3 that contains a Sec7-like domain. Proc Natl. Acad. Sci. USA 93, 12856-12860 (1996).
12. Renault, L., Guibert, B. & Cherfils, J. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 426 (suppl. 6966): 525-530 (2003).
13. Mossessova, E., Corpina, R.A. f Goldberg, J. Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implicatioms for the guanine nucleotide exchange mechanism. Mol Cell 12 (suppl. 6): 1403-1411 (2003).
14. Cherfils, J. & Melancon, P. On the action of Brefeldin A on Sec7-stimulated membrane-recruitment and GDP/GTP exchartge of ARF proteins. Biochem. Soc. Trans. 33 (Part 4): 635-638 (2005).
15. Brody, E.N. & Gold, L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74 (suppt. 1): 5-13 (2000).
16. Famulok, M., Hartig, J.S. & Mayer, G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem. Rev. 107 (suppl. 9):3715-3743 (2007).
17. Mayer, G. et al. Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers. Proc Natl. Acad. Sci. USA 98 (suppl. 9): 4961-4965 (2001).
18. Theis, M.G. et al. Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2. Proc Natl. Acad. Sci. USA 101 (suppl. 31): 11221-11226 (2004).
19. Chardin, P. et al. A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains. Nature 384 (suppl. 6608): 481-484 (1996).
20. Meaci, E. et al. Cytohesin-1, a cytosolic guanine nucleotide-exchange protein for ADP-ribosylation factor. Proc. Natl. Acad Sci. USA 94 (suppl. 5): 1745-1748 (1997).
21. Kolanus, W. et al. αLβ2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule. Cell 86 (suppl. 2): 233-242 (1996).
22. Hafner, M. et al. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature 444 (suppl. 7121): 941-944 (2006).
23. Fuss, B., Becker, T., Zinke, I. & Hoch, M. The cytohesin Steppke is essential for insulin signalling in Drosophila. Nature 444 (suppl. 7121): 945-948 (2006).
24. Blind, M., Kolanus, W. & Famulok, M. Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. Proc. Natl. Acad. Sci. USA 96 (suppl. 7): 3606-3610 (1999).
25. Shi, H., Hoffman, B.E. & Lis, J.T. RNA aptamers as effective protein antagonists in a multicellular organism. Proc. Natl. Acad. Sci. USA 96 (suppl. 18): 10033-10038 (1999).
26. Hartig, J.S. et al. Protein-dependent ribozymes report molecular interactions in real time. Nat. Biotechnol. 20 (suppl. 7): 717-722 (2002).
27. Yamazaki, S. et al. Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol. 14 (suppl. 7): 804-812 (2007).
28. Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A simpte statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (suppl. 2): 67-73 (1999).
29. Knight, S.M. et al. A fluorescence polarization assay for the identification of inhibitors of the p53-DM2 protein-protein interaction. Anal. Biochem. 300 (suppl. 2): 230-236 (2002).
30. Maurer, H.H. & Fritz, C.F. Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometry. Int. J. Legal Med. 104 (suppl. 1): 43-46 (1990).
31. Wu, P., Brasseur, M. & Schindler, U. A high-throughput STAT binding assay using fluorescence polarization. Anal. Biochem. 249 (suppl. 1): 29-36 (1997).
32. Frank, D.N., Ellington, A.E. & Pace, N.R. In vitro selection of RNase P RNA reveals optimized catalytic activity in a highly conserved structural domain. RNA 2 (suppl 12): 1179-1189 (1996).
33. Murphy, R.F., Jorgensen, E.D. & Cantor, C.R. Kinetics of histone endocytosis in Chinese hamster ovary cells. A flow cytofluorometric analysis. J. Biol. Chem. 257 (suppl. 4): 1695-1701 (1982).
34. Wu, T.P., Ruan, K.C. & Liu, W.Y. A fluorescence-labeling method for sequencing small RNA on polyacrylamide gel. Nucl. Acids Res. 24 (suppl. 17): 3472-3473 (1996).
35. Huang, X. Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J. Biomol. Screen. 8 (suppl. 1): 34-38 (2003).
36. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (suppl. 1-3): 3-26 (2001).
37. Gopinath, S.C. Methods developed for SELEX. Anal. Bioanal. Chem. 387 (suppl 1): 171-132 (2007).
38. Klug, S.J. & Famulok, M. All you wanted to know about SELEX. Mol. Biol. Rep. 20 (suppl 2): 97-107 (1994).
39. Fitzwater, T. & Polisky, B. in Methods in Enzymology Vol. 267 (ed. Abelson, J.N.) 275-301 (Academic Press, San Diego, CA, 1996).
40. Moore, D.D. & Dowhan, D. in Current Protocols in Molecular Biology (ed. Ausubel, F.M. et al. 2.1.1. (John Wiley & Sons Inc., New York, 2003).
41. Sengle, G. et al. Synthesis, incorporation efficiency, and stability of disulfide bridged functional groups at RNA 5′-ends. Bioorg. Med. Chem. 8 (suppl. 6): 1317-1329 (2000).